

**Date of preparation:** 28 January 2026

**Issuer's abbreviated name:** SYNEKTIK SA

**Current report:** 10/2026 ESPI

**Subject:** Information on the conclusion of a significant agreement on the sale of robotic systems

**Legal basis:** Article 17 Section 1 of MAR – confidential information

**Body of the report:**

Time of publication: 12:52 p.m.

The Management Board of Synektik SA (Company) reports that the Company has concluded significant agreement with Świętokrzyskie Centrum Onkologii w Kielcach [Świętokrzyskie Oncology Centre in Kielce] with its registered office at: ul. Artwińskiego 3C, 25-734 Kielce (Hospital).

This agreement pertains to the supply, assembly, installation and commissioning of the da Vinci robotic surgery system and with additional fixings, staff training and warranty maintenance.

This agreement was concluded as a result of a public tender proceeding conducted in the form of an unlimited tender for the net amount of PLN 18,348,297.90.

The delivery of robotic technology will take place within 84 days of concluding the agreement. The warranty period for system delivery is 60 months from signing the final acceptance reports. The other clauses in the agreement concluded by the Company do not deviate from the standards generally used in contracts of this type.

The signing of this agreement was deemed to be significant by the Management Board of Synektik SA since its net value exceed 5% of the equity of the Synektik Group disclosed in its last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting standards. The proceeds generated by delivery of the robotic system will affect the sales results in the 2025 financial year lasting from 1 October 2025 to 30 September 2026.



**Persons representing the Issuer:**

Cezary Kozanecki – President of the  
Management Board